Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
- Status
- TERMINATED
- Phase
- PHASE2
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2